Ascendis Pharma (ASND)
(Real Time Quote from BATS)
$129.25 USD
-7.28 (-5.33%)
Updated Aug 2, 2024 10:40 AM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASND 129.25 -7.28(-5.33%)
Will ASND be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Other News for ASND
Morgan Stanley Sticks to Its Hold Rating for Ascendis Pharma (ASND)
Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy Opportunity
Morgan Stanley Remains a Hold on Ascendis Pharma (ASND)
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Ascendis Pharma Outlines Capital Strategy